Camizestrant Links ESR1 Detection to Breast Cancer Care
Episode Summary
FDA approved camizestrant for eligible ESR1-mutated advanced breast cancer, enabling mutation-guided endocrine switching before radiographic progression while continuing CDK4/6 inhibitor therapy.